Search research articles
Contact Us
Filters
Showing results (141-150 of 146) with videos related to
Page
of 15
Sort By:
You have reached the last page of results.
This site can display upto 146 results.
Nature Communications
|
September 8, 2021
Single-nuclei transcriptomes from human adrenal gland reveal distinct cellular identities of low and high-risk neuroblastoma tumors
O C Bedoya-Reina, W Li, M Arceo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 7, 2022
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC
A A Bokhari, W-Y Lai, A T Le, et al.
Disease Models & Mechanisms
|
August 3, 2016
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
J Guan, E R Tucker, H Wan, et al.
Cytogenetics and Cell Genetics
|
January 1, 1996
Report of the sixth international workshop on human chromosome 3 mapping 1995
S L Naylor, B Carritt, C Boileau, et al.
British Journal of Cancer
|
October 31, 2014
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification
R Defferrari, K Mazzocco, I M Ambros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2003
Quality assessment of genetic markers used for therapy stratification
I M Ambros, J Benard, M Boavida, et al.
Page
of 15
Search research articles
Search
Showing results (141-150 of 146) with videos related to
Sort By:
Page
of 15
You have reached the last page of results.
This site can display upto 146 results.
Nature Communications
|
September 8, 2021
Single-nuclei transcriptomes from human adrenal gland reveal distinct cellular identities of low and high-risk neuroblastoma tumors
O C Bedoya-Reina, W Li, M Arceo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 7, 2022
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC
A A Bokhari, W-Y Lai, A T Le, et al.
Disease Models & Mechanisms
|
August 3, 2016
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
J Guan, E R Tucker, H Wan, et al.
Cytogenetics and Cell Genetics
|
January 1, 1996
Report of the sixth international workshop on human chromosome 3 mapping 1995
S L Naylor, B Carritt, C Boileau, et al.
British Journal of Cancer
|
October 31, 2014
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification
R Defferrari, K Mazzocco, I M Ambros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2003
Quality assessment of genetic markers used for therapy stratification
I M Ambros, J Benard, M Boavida, et al.
Page
of 15